Group 1 - The company,药捷安康, announced a financing plan through the placement of new H-shares, issuing 2,100,000 shares to raise approximately HKD 195 million, with net proceeds expected to be around HKD 190 million after expenses [1] - The placement price of HKD 92.85 represents an approximately 18.0% discount to the closing price of HKD 113.20 on the previous trading day and an 18.3% discount to the average closing price of HKD 113.66 over the last five trading days [1] - The newly issued shares will account for about 0.53% of the existing issued share capital and will also represent approximately 0.53% of the enlarged share capital post-issuance [1] Group 2 - The funds raised will primarily be allocated to the clinical trials of the core product Tinengotinib, as well as for the development of other products, operational funding, and general corporate purposes [1] - The issuance is conducted under a general authorization granted by the shareholders' meeting and is expected to be completed by January 21, 2026 [1] - The company focuses on discovering and developing innovative small molecule therapies for oncology, inflammation, and cardiovascular metabolic diseases, positioning itself as a clinical demand-driven innovative pharmaceutical company [1]

Core Viewpoint - The strategic partnership between Hanyu Pharmaceutical and KuCoin aims to explore the tokenization of future revenue rights from innovative drug research and development in Hong Kong, marking a significant step in the integration of technology, medicine, and finance [1][2][3] Group 1: Company Overview - Hanyu Pharmaceutical has over 20 years of experience in peptide drugs and possesses a comprehensive formulation pipeline covering mainstream peptide targets globally [3] - The company expects a substantial increase in net profit for the first half of 2025, projecting between 142 million to 162 million yuan, representing a year-on-year growth of 1,471% to 1,664% [3] - Hanyu's collaboration with KuCoin is expected to enhance its competitive edge in the GLP-1 peptide drug sector by leveraging blockchain technology [6] Group 2: Industry Context - The pharmaceutical industry faces high research costs, lengthy development cycles, and significant risks, making capital market financing essential for many innovative drug companies [4] - Traditional financing models often rely on private equity and venture capital, leading to dilution of equity and uncertainty regarding IPO success [4][5] - The emergence of the RWA model represents a new financing solution, allowing the tokenization of intangible assets, which can facilitate broader investor participation and reduce reliance on traditional intermediaries [5][6] Group 3: Technological Integration - KuCoin's capabilities include ensuring a clear patent foundation for Hanyu's GLP-1 pipeline and converting key milestones into programmable revenue rights for tokenization [6] - The implementation of the RWA model under the new stablecoin regulations in Hong Kong is expected to enhance legal compliance and reduce trust costs, thereby protecting investor rights [6] - Successful execution of this model could establish a new paradigm for financing in China's innovative drug development sector, promoting digitalization and globalization [6]

Core Viewpoint - The strategic partnership between Hanyu Pharmaceutical and KuCoin aims to explore the tokenization of future revenue rights from innovative drug research and development in Hong Kong, marking a significant step in the integration of technology, finance, and pharmaceuticals under the new stablecoin regulations [1][3][4]. Group 1: Partnership Details - Hanyu Pharmaceutical has partnered with KuCoin to leverage its expertise in blockchain technology and RWA (Real World Asset) solutions for the tokenization of intangible assets related to drug development [2][3]. - KuCoin, established in 2017, has over 40 million registered users and ranks fourth globally in futures trading, with a daily trading volume exceeding $6.1 billion [2]. - The collaboration is positioned as a response to the new regulatory environment in Hong Kong, aiming to transform the valuation and trading of intangible assets in the pharmaceutical sector [3][4]. Group 2: Hanyu Pharmaceutical's Strengths - Hanyu Pharmaceutical's core competencies lie in its extensive GLP-1 peptide drug pipeline and over 500 patents, which provide a significant technological barrier [3][4]. - The company anticipates a substantial increase in net profit for the first half of 2025, projecting between 142 million to 162 million yuan, representing a year-on-year growth of 1,471% to 1,664% [4]. - Recent collaborations, including a partnership with Carbon Cloud Peptide for the development of a new GLP-1R/GIPR/GCGR triple agonist, highlight the company's rapid global expansion and innovation [4]. Group 3: Implications for the Industry - The partnership is expected to create a new paradigm for international pricing and financing of Chinese innovative drugs, addressing the high costs and risks associated with drug development [5][6]. - The RWA model offers a solution to the uncertainties of traditional financing methods, allowing for the tokenization of intangible assets and broader investor participation [6][7]. - Successful implementation of the RWA model could enhance Hanyu Pharmaceutical's competitive edge in the GLP-1 drug sector and set a precedent for future pharmaceutical RWA projects in China [7].